Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) practical guide for peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-Oxodotreotide in gastroenteropancreatic neuroendocrine tumors (GEP-NET) Article Swipe
Riccardo Laudicella
,
Domenico Albano
,
Matteo Bauckneht
,
Luca Urso
,
Lisa Bodei
,
Maria Luisa De Rimini
,
Chiara Maria Grana
,
Sergio Baldari
,
Annibale Versari
,
Angelina Filice
,
Mirco Bartolomei
,
Marco Maccauro
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1007/s40336-025-00679-y
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1007/s40336-025-00679-y
Somatostatin receptors (SSTR) are overexpressed by most neuroendocrine tumors (NETs), and patients with SSTR-positive disease can be identified by DOTA-peptide PET. Phase II and III studies proved SSTR-targeted radiopharmaceutical therapy safe and effective in metastatic gastroenteropancreatic (GEP) NETs progressed after SST analogues. Additional data indicate that [ 177 Lu]Lu-oxodotreotide peptide receptor radionuclide therapy (PRRT) also has high potential in earlier clinical situations. The purpose of this Italian procedural guideline is to assist the nuclear medicine personnel in the delivery of [ 177 Lu]Lu-DOTA-peptide therapy, from patient selection to end-of-therapy follow-up, and to facilitate the management of possible side effects and their clinical management. The current document is based upon the current best practice and knowledge of experienced Centers and Nuclear Medicine Physicians in Italy.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1007/s40336-025-00679-y
- OA Status
- hybrid
- Cited By
- 2
- References
- 39
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4407364930
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4407364930Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1007/s40336-025-00679-yDigital Object Identifier
- Title
-
Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) practical guide for peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-Oxodotreotide in gastroenteropancreatic neuroendocrine tumors (GEP-NET)Work title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-02-12Full publication date if available
- Authors
-
Riccardo Laudicella, Domenico Albano, Matteo Bauckneht, Luca Urso, Lisa Bodei, Maria Luisa De Rimini, Chiara Maria Grana, Sergio Baldari, Annibale Versari, Angelina Filice, Mirco Bartolomei, Marco MaccauroList of authors in order
- Landing page
-
https://doi.org/10.1007/s40336-025-00679-yPublisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1007/s40336-025-00679-yDirect OA link when available
- Concepts
-
Peptide receptor, Radionuclide therapy, Medicine, Neuroendocrine tumors, Nuclear medicine, Nuclear medicine imaging, Radiation therapy, Internal medicine, Molecular imaging, Radionuclide imaging, Medical physics, Oncology, Receptor, In vivo, Biology, BiotechnologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
2Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 2Per-year citation counts (last 5 years)
- References (count)
-
39Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4407364930 |
|---|---|
| doi | https://doi.org/10.1007/s40336-025-00679-y |
| ids.doi | https://doi.org/10.1007/s40336-025-00679-y |
| ids.openalex | https://openalex.org/W4407364930 |
| fwci | 9.20270099 |
| type | article |
| title | Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) practical guide for peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-Oxodotreotide in gastroenteropancreatic neuroendocrine tumors (GEP-NET) |
| biblio.issue | 2 |
| biblio.volume | 13 |
| biblio.last_page | 120 |
| biblio.first_page | 105 |
| topics[0].id | https://openalex.org/T10754 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2713 |
| topics[0].subfield.display_name | Epidemiology |
| topics[0].display_name | Neuroendocrine Tumor Research Advances |
| topics[1].id | https://openalex.org/T12334 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9983999729156494 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Lung Cancer Research Studies |
| topics[2].id | https://openalex.org/T12226 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9975000023841858 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2728 |
| topics[2].subfield.display_name | Neurology |
| topics[2].display_name | Neuroblastoma Research and Treatments |
| is_xpac | False |
| apc_list.value | 3060 |
| apc_list.currency | EUR |
| apc_list.value_usd | 3860 |
| apc_paid.value | 3060 |
| apc_paid.currency | EUR |
| apc_paid.value_usd | 3860 |
| concepts[0].id | https://openalex.org/C3017732841 |
| concepts[0].level | 3 |
| concepts[0].score | 0.9397738575935364 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q25098597 |
| concepts[0].display_name | Peptide receptor |
| concepts[1].id | https://openalex.org/C2993559085 |
| concepts[1].level | 2 |
| concepts[1].score | 0.9348883628845215 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q2126444 |
| concepts[1].display_name | Radionuclide therapy |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.8103297352790833 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2779066768 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6477124691009521 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1981276 |
| concepts[3].display_name | Neuroendocrine tumors |
| concepts[4].id | https://openalex.org/C2989005 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5073732733726501 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q214963 |
| concepts[4].display_name | Nuclear medicine |
| concepts[5].id | https://openalex.org/C2994052390 |
| concepts[5].level | 2 |
| concepts[5].score | 0.46086299419403076 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q214963 |
| concepts[5].display_name | Nuclear medicine imaging |
| concepts[6].id | https://openalex.org/C509974204 |
| concepts[6].level | 2 |
| concepts[6].score | 0.45364782214164734 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q180507 |
| concepts[6].display_name | Radiation therapy |
| concepts[7].id | https://openalex.org/C126322002 |
| concepts[7].level | 1 |
| concepts[7].score | 0.4384858012199402 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[7].display_name | Internal medicine |
| concepts[8].id | https://openalex.org/C136339569 |
| concepts[8].level | 3 |
| concepts[8].score | 0.42121976613998413 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1142297 |
| concepts[8].display_name | Molecular imaging |
| concepts[9].id | https://openalex.org/C2992596254 |
| concepts[9].level | 2 |
| concepts[9].score | 0.414737731218338 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q214963 |
| concepts[9].display_name | Radionuclide imaging |
| concepts[10].id | https://openalex.org/C19527891 |
| concepts[10].level | 1 |
| concepts[10].score | 0.34093207120895386 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q1120908 |
| concepts[10].display_name | Medical physics |
| concepts[11].id | https://openalex.org/C143998085 |
| concepts[11].level | 1 |
| concepts[11].score | 0.32214540243148804 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[11].display_name | Oncology |
| concepts[12].id | https://openalex.org/C170493617 |
| concepts[12].level | 2 |
| concepts[12].score | 0.2339489758014679 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q208467 |
| concepts[12].display_name | Receptor |
| concepts[13].id | https://openalex.org/C207001950 |
| concepts[13].level | 2 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q141124 |
| concepts[13].display_name | In vivo |
| concepts[14].id | https://openalex.org/C86803240 |
| concepts[14].level | 0 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[14].display_name | Biology |
| concepts[15].id | https://openalex.org/C150903083 |
| concepts[15].level | 1 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7108 |
| concepts[15].display_name | Biotechnology |
| keywords[0].id | https://openalex.org/keywords/peptide-receptor |
| keywords[0].score | 0.9397738575935364 |
| keywords[0].display_name | Peptide receptor |
| keywords[1].id | https://openalex.org/keywords/radionuclide-therapy |
| keywords[1].score | 0.9348883628845215 |
| keywords[1].display_name | Radionuclide therapy |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.8103297352790833 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/neuroendocrine-tumors |
| keywords[3].score | 0.6477124691009521 |
| keywords[3].display_name | Neuroendocrine tumors |
| keywords[4].id | https://openalex.org/keywords/nuclear-medicine |
| keywords[4].score | 0.5073732733726501 |
| keywords[4].display_name | Nuclear medicine |
| keywords[5].id | https://openalex.org/keywords/nuclear-medicine-imaging |
| keywords[5].score | 0.46086299419403076 |
| keywords[5].display_name | Nuclear medicine imaging |
| keywords[6].id | https://openalex.org/keywords/radiation-therapy |
| keywords[6].score | 0.45364782214164734 |
| keywords[6].display_name | Radiation therapy |
| keywords[7].id | https://openalex.org/keywords/internal-medicine |
| keywords[7].score | 0.4384858012199402 |
| keywords[7].display_name | Internal medicine |
| keywords[8].id | https://openalex.org/keywords/molecular-imaging |
| keywords[8].score | 0.42121976613998413 |
| keywords[8].display_name | Molecular imaging |
| keywords[9].id | https://openalex.org/keywords/radionuclide-imaging |
| keywords[9].score | 0.414737731218338 |
| keywords[9].display_name | Radionuclide imaging |
| keywords[10].id | https://openalex.org/keywords/medical-physics |
| keywords[10].score | 0.34093207120895386 |
| keywords[10].display_name | Medical physics |
| keywords[11].id | https://openalex.org/keywords/oncology |
| keywords[11].score | 0.32214540243148804 |
| keywords[11].display_name | Oncology |
| keywords[12].id | https://openalex.org/keywords/receptor |
| keywords[12].score | 0.2339489758014679 |
| keywords[12].display_name | Receptor |
| language | en |
| locations[0].id | doi:10.1007/s40336-025-00679-y |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2764895717 |
| locations[0].source.issn | 2281-5872, 2281-7565 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 2281-5872 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Clinical and Translational Imaging |
| locations[0].source.host_organization | https://openalex.org/P4310319900 |
| locations[0].source.host_organization_name | Springer Science+Business Media |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310319900 |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Clinical and Translational Imaging |
| locations[0].landing_page_url | https://doi.org/10.1007/s40336-025-00679-y |
| locations[1].id | pmh:oai:sfera.unife.it:11392/2583330 |
| locations[1].is_oa | False |
| locations[1].source | |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | info:eu-repo/semantics/article |
| locations[1].license_id | |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | |
| locations[1].landing_page_url | https://hdl.handle.net/11392/2583330 |
| locations[2].id | pmh:oai:iris.unibs.it:11379/622725 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306400804 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Institutional Research Information System (Università degli Studi di Brescia) |
| locations[2].source.host_organization | https://openalex.org/I66752286 |
| locations[2].source.host_organization_name | University of Milano-Bicocca |
| locations[2].source.host_organization_lineage | https://openalex.org/I66752286 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | info:eu-repo/semantics/article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | https://hdl.handle.net/11379/622725 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5033465412 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-2842-0301 |
| authorships[0].author.display_name | Riccardo Laudicella |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Riccardo Laudicella |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5085849378 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-0810-6494 |
| authorships[1].author.display_name | Domenico Albano |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Domenico Albano |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5038942338 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-1937-9116 |
| authorships[2].author.display_name | Matteo Bauckneht |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Matteo Bauckneht |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5016594495 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-3007-3898 |
| authorships[3].author.display_name | Luca Urso |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Luca Urso |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5020320888 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-6930-7383 |
| authorships[4].author.display_name | Lisa Bodei |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Lisa Bodei |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5039122933 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-9754-1721 |
| authorships[5].author.display_name | Maria Luisa De Rimini |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Maria Luisa De Rimini |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5042452114 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-3808-2174 |
| authorships[6].author.display_name | Chiara Maria Grana |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Chiara Maria Grana |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5052879426 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-4652-725X |
| authorships[7].author.display_name | Sergio Baldari |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Sergio Baldari |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5045569134 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-8675-2435 |
| authorships[8].author.display_name | Annibale Versari |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Annibale Versari |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5088256436 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-8483-1933 |
| authorships[9].author.display_name | Angelina Filice |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Angelina Filice |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5017138113 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-6474-4143 |
| authorships[10].author.display_name | Mirco Bartolomei |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Mirco Bartolomei |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5028413341 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-1389-3250 |
| authorships[11].author.display_name | Marco Maccauro |
| authorships[11].author_position | last |
| authorships[11].raw_author_name | Marco Maccauro |
| authorships[11].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1007/s40336-025-00679-y |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) practical guide for peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-Oxodotreotide in gastroenteropancreatic neuroendocrine tumors (GEP-NET) |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10754 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2713 |
| primary_topic.subfield.display_name | Epidemiology |
| primary_topic.display_name | Neuroendocrine Tumor Research Advances |
| related_works | https://openalex.org/W4249559563, https://openalex.org/W1987488764, https://openalex.org/W2551380454, https://openalex.org/W3016834638, https://openalex.org/W4390490664, https://openalex.org/W2793548483, https://openalex.org/W3031062288, https://openalex.org/W1516732200, https://openalex.org/W3118580091, https://openalex.org/W2902656640 |
| cited_by_count | 2 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 2 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1007/s40336-025-00679-y |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764895717 |
| best_oa_location.source.issn | 2281-5872, 2281-7565 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 2281-5872 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Clinical and Translational Imaging |
| best_oa_location.source.host_organization | https://openalex.org/P4310319900 |
| best_oa_location.source.host_organization_name | Springer Science+Business Media |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310319900 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Clinical and Translational Imaging |
| best_oa_location.landing_page_url | https://doi.org/10.1007/s40336-025-00679-y |
| primary_location.id | doi:10.1007/s40336-025-00679-y |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2764895717 |
| primary_location.source.issn | 2281-5872, 2281-7565 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 2281-5872 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Clinical and Translational Imaging |
| primary_location.source.host_organization | https://openalex.org/P4310319900 |
| primary_location.source.host_organization_name | Springer Science+Business Media |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310319900 |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Clinical and Translational Imaging |
| primary_location.landing_page_url | https://doi.org/10.1007/s40336-025-00679-y |
| publication_date | 2025-02-12 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W2573369749, https://openalex.org/W2663808291, https://openalex.org/W2808537568, https://openalex.org/W3005237187, https://openalex.org/W4318817556, https://openalex.org/W2125398839, https://openalex.org/W3109798735, https://openalex.org/W3133235753, https://openalex.org/W1973304341, https://openalex.org/W2953400654, https://openalex.org/W3027911564, https://openalex.org/W2971385112, https://openalex.org/W1143210258, https://openalex.org/W2108613323, https://openalex.org/W2971523720, https://openalex.org/W3132615335, https://openalex.org/W4308373296, https://openalex.org/W2031048655, https://openalex.org/W2024035978, https://openalex.org/W2117584693, https://openalex.org/W4232736732, https://openalex.org/W3041637921, https://openalex.org/W2010599483, https://openalex.org/W2607151521, https://openalex.org/W3165069504, https://openalex.org/W2146875238, https://openalex.org/W2792415980, https://openalex.org/W4224443423, https://openalex.org/W2743184713, https://openalex.org/W2116796427, https://openalex.org/W2090257199, https://openalex.org/W2767946527, https://openalex.org/W2809957686, https://openalex.org/W2373606074, https://openalex.org/W2128334754, https://openalex.org/W2790686754, https://openalex.org/W2599795450, https://openalex.org/W2598918446, https://openalex.org/W3015314028 |
| referenced_works_count | 39 |
| abstract_inverted_index.[ | 47, 81 |
| abstract_inverted_index.II | 23 |
| abstract_inverted_index.be | 17 |
| abstract_inverted_index.by | 6, 19 |
| abstract_inverted_index.in | 34, 59, 77, 123 |
| abstract_inverted_index.is | 70, 107 |
| abstract_inverted_index.of | 65, 80, 96, 116 |
| abstract_inverted_index.to | 71, 88, 92 |
| abstract_inverted_index.177 | 48, 82 |
| abstract_inverted_index.III | 25 |
| abstract_inverted_index.SST | 41 |
| abstract_inverted_index.The | 63, 104 |
| abstract_inverted_index.and | 11, 24, 32, 91, 100, 114, 119 |
| abstract_inverted_index.are | 4 |
| abstract_inverted_index.can | 16 |
| abstract_inverted_index.has | 56 |
| abstract_inverted_index.the | 73, 78, 94, 110 |
| abstract_inverted_index.NETs | 38 |
| abstract_inverted_index.PET. | 21 |
| abstract_inverted_index.also | 55 |
| abstract_inverted_index.best | 112 |
| abstract_inverted_index.data | 44 |
| abstract_inverted_index.from | 85 |
| abstract_inverted_index.high | 57 |
| abstract_inverted_index.most | 7 |
| abstract_inverted_index.safe | 31 |
| abstract_inverted_index.side | 98 |
| abstract_inverted_index.that | 46 |
| abstract_inverted_index.this | 66 |
| abstract_inverted_index.upon | 109 |
| abstract_inverted_index.with | 13 |
| abstract_inverted_index.(GEP) | 37 |
| abstract_inverted_index.Phase | 22 |
| abstract_inverted_index.after | 40 |
| abstract_inverted_index.based | 108 |
| abstract_inverted_index.their | 101 |
| abstract_inverted_index.(PRRT) | 54 |
| abstract_inverted_index.(SSTR) | 3 |
| abstract_inverted_index.Italy. | 124 |
| abstract_inverted_index.assist | 72 |
| abstract_inverted_index.proved | 27 |
| abstract_inverted_index.tumors | 9 |
| abstract_inverted_index.(NETs), | 10 |
| abstract_inverted_index.Centers | 118 |
| abstract_inverted_index.Italian | 67 |
| abstract_inverted_index.Nuclear | 120 |
| abstract_inverted_index.current | 105, 111 |
| abstract_inverted_index.disease | 15 |
| abstract_inverted_index.earlier | 60 |
| abstract_inverted_index.effects | 99 |
| abstract_inverted_index.nuclear | 74 |
| abstract_inverted_index.patient | 86 |
| abstract_inverted_index.peptide | 50 |
| abstract_inverted_index.purpose | 64 |
| abstract_inverted_index.studies | 26 |
| abstract_inverted_index.therapy | 30, 53 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Medicine | 121 |
| abstract_inverted_index.clinical | 61, 102 |
| abstract_inverted_index.delivery | 79 |
| abstract_inverted_index.document | 106 |
| abstract_inverted_index.indicate | 45 |
| abstract_inverted_index.medicine | 75 |
| abstract_inverted_index.patients | 12 |
| abstract_inverted_index.possible | 97 |
| abstract_inverted_index.practice | 113 |
| abstract_inverted_index.receptor | 51 |
| abstract_inverted_index.therapy, | 84 |
| abstract_inverted_index.effective | 33 |
| abstract_inverted_index.guideline | 69 |
| abstract_inverted_index.knowledge | 115 |
| abstract_inverted_index.personnel | 76 |
| abstract_inverted_index.potential | 58 |
| abstract_inverted_index.receptors | 2 |
| abstract_inverted_index.selection | 87 |
| abstract_inverted_index.Additional | 43 |
| abstract_inverted_index.Physicians | 122 |
| abstract_inverted_index.analogues. | 42 |
| abstract_inverted_index.facilitate | 93 |
| abstract_inverted_index.follow-up, | 90 |
| abstract_inverted_index.identified | 18 |
| abstract_inverted_index.management | 95 |
| abstract_inverted_index.metastatic | 35 |
| abstract_inverted_index.procedural | 68 |
| abstract_inverted_index.progressed | 39 |
| abstract_inverted_index.experienced | 117 |
| abstract_inverted_index.management. | 103 |
| abstract_inverted_index.situations. | 62 |
| abstract_inverted_index.DOTA-peptide | 20 |
| abstract_inverted_index.Somatostatin | 1 |
| abstract_inverted_index.radionuclide | 52 |
| abstract_inverted_index.SSTR-positive | 14 |
| abstract_inverted_index.SSTR-targeted | 28 |
| abstract_inverted_index.overexpressed | 5 |
| abstract_inverted_index.end-of-therapy | 89 |
| abstract_inverted_index.neuroendocrine | 8 |
| abstract_inverted_index.Lu]Lu-DOTA-peptide | 83 |
| abstract_inverted_index.Lu]Lu-oxodotreotide | 49 |
| abstract_inverted_index.radiopharmaceutical | 29 |
| abstract_inverted_index.gastroenteropancreatic | 36 |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 95 |
| countries_distinct_count | 0 |
| institutions_distinct_count | 12 |
| citation_normalized_percentile.value | 0.93284847 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |